Amgen Inc., of Thousand Oaks, Calif., reported results from the final analysis of the phase III ASPIRE trial, showing it met the key secondary endpoint of overall survival (OS), with proteasome inhibitor Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide, Celgene Corp.) and dexamethasone (KRd), reducing the risk of death by 21 percent over lenalidomide and dexamethasone alone (Rd) (median OS 48.3 months for KRd vs. 40.4 months for Rd, HR = 0.79, 95 percent CI, 0.67 – 0.95).